Accurate de novo design of hyperstable constrained peptides

Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks generally have shapes evolved to fit precisely into binding pockets on their targets. Such peptides can have excellent pharmaceutical properties, combining the stability and tissue penetration of small molecu...

Full description

Bibliographic Details
Main Authors: Bhardwaj, Gaurav, Mulligan, Vikram Khipple, Bahl, Christopher D., Gilmore, Jason M., Harvey, Peta J., Cheneval, Olivier, Buchko, Garry W., Pulavarti, Surya V.S.R.K., Kaas, Quentin, Eletsky, Alexander, Huang, Po-Ssu, Johnsen, William A., Greisen, Per, Rocklin, Gabriel J., Song, Yifan, Linsky, Thomas W., Watkins, Andrew, Rettie, Stephen A., Xu, Xianzhong, Carter, Lauren P., Bonneau, Richard, Olson, James M., Coutsias, Evangelos, Correnti, Colin E., Szyperski, Thomas, Craik, David J., Baker, David
Format: Online
Language:English
Published: 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161715/
Description
Summary:Naturally occurring, pharmacologically active peptides constrained with covalent crosslinks generally have shapes evolved to fit precisely into binding pockets on their targets. Such peptides can have excellent pharmaceutical properties, combining the stability and tissue penetration of small molecule drugs with the specificity of much larger protein therapeutics. The ability to design constrained peptides with precisely specified tertiary structures would enable the design of shape-complementary inhibitors of arbitrary targets. Here we describe the development of computational methods for de novo design of conformationally-restricted peptides, and the use of these methods to design 15–50 residue disulfide-crosslinked and heterochiral N-C backbone-cyclized peptides. These peptides are exceptionally stable to thermal and chemical denaturation, and twelve experimentally-determined X-ray and NMR structures are nearly identical to the computational models. The computational design methods and stable scaffolds presented here provide the basis for development of a new generation of peptide-based drugs.